Anti-Aging gene therapy trial launches in healthy volunteers
NCT ID NCT07285629
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-phase study tests a gene therapy that delivers two proteins, klotho and follistatin, via injection into healthy adults aged 50 to 80. The goal is to see if it safely raises these protein levels and improves health or cognition. Thirty participants will be monitored for side effects and changes in quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Apeiron Center
RECRUITINGAustin, Texas, 78701, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Global Alliance of Regenerative Medicine (GARM) Clinic
NOT_YET_RECRUITINGRoatán, Bay Islands, Honduras
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
klotho and follistatin gene therapy (nonviral plasmid injection)
What this could lead to
If successful, this could point toward a gene therapy that slows aging or improves cognitive function in older adults.
What could go wrong
This is a very early, small pilot study with only 30 healthy volunteers. It may not show clear benefits, and safety risks from gene therapy are still unknown.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.